Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep587 | Endocrine-Related Cancer | ECE2022

Poor outcome of systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan Kazhan , Skogseid Britt , Botling Johan , AEkerstrom Tobias , Eriksson Barbro , Welin Staffan , Anders Sundin , Crona Joakim

Introduction: Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3, that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. Methods: This was a single center retrospective cohort study, aimed to characterize treatment patterns and outcomes among patie...

ea0049gp194 | Pituitary & endocrine Tumours | ECE2017

Serotonin, ATRX and DAXX as differential diagnostic markers of neuroendocrine tumours (NETs) in the sellar region. An immunohistochemical study in a large series of pituitary adenomas and in a non-pituitary NET

Casar-Borota Olivera , Botling Johan , Granberg Dan , Wikstrom Johan , Ponten Fredrik , Trouillas Jacqueline

We present a case of a patient with a locally invasive, serotonin- and ACTH-reactive tumour in the sellar region, filling the sphenoid sinus and expanding into the epipharynx. Clinical examination completed by 68-Gallium-DOTA-TOC PET revealed tracer uptake in the sellar tumour as well as in a 7 mm lesion in the pancreatic tail. A differential diagnosis between silent corticotroph adenoma and another primary or secondary neuroendocrine tumour (NET) with ACTH-expression was diff...